IHH Annual Report 2023

Name of subsidiary Place of incorporation and business Principal activities Effective ownership interest and voting interest 2023 % 2022 % Indirect subsidiaries (continued) Held through Integrated Healthcare Turkey Yatirimlari Limited: Integrated Healthcare Hastaneler Turkey Sdn. Bhd. Malaysia Investment holding 100 100 Held through IHH Laboratories Holdings Sdn. Bhd.: IHH Laboratories Pte. Ltd. # Singapore Investment holding and provision of services for medical diagnostic laboratory tests 100 100 Held through Parkway Pantai Limited: Parkway HK Holdings Limited #(1) Hong Kong Investment holding 100 100 Parkway Holdings Limited # Singapore Investment holding 100 100 Pantai Holdings Sdn. Bhd. Malaysia Investment holding 100 100 Parkway Group Healthcare Pte. Ltd. #(2) Singapore Investment holding and provision of technical support and consultancy services 100 100 Gleneagles Development Pte. Ltd. #(3) Singapore Investment holding 100 100 Parkway Healthcare Indo-China Pte. Ltd. # Singapore Investment holding 100 100 Northern TK Venture Pte. Ltd. # Singapore Investment holding 100 100 Angsana Holdings Pte. Ltd. # Singapore Investment holding – 55.00 Held through Integrated Healthcare Hastaneler Turkey Sdn. Bhd.: Acibadem Saglik Yatirımlari Holding A.S. # Türkiye Investment holding 90.00 90.00 Held through IHH Laboratories Pte. Ltd.: Parkway Laboratory Services Ltd. #(16) Singapore Provision of comprehensive diagnostic laboratory services 100 100 Premier Integrated Labs Sdn. Bhd. (f.k.a. Pantai Premier Pathology Sdn. Bhd.) (16) Malaysia Provision of medical laboratory services 100 100 Annual Report 2023 231 41. SUBSIDIARIES (continued)

RkJQdWJsaXNoZXIy NDgzMzc=